Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 11.00
CEMP's Cash to Debt is ranked lower than
57% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. CEMP: 11.00 )
Ranked among companies with meaningful Cash to Debt only.
CEMP' s 10-Year Cash to Debt Range
Min: 1.12  Med: 7.36 Max: No Debt
Current: 11
Equity to Asset 0.78
CEMP's Equity to Asset is ranked higher than
63% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CEMP: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
CEMP' s 10-Year Equity to Asset Range
Min: 0.48  Med: 0.71 Max: 0.82
Current: 0.78
0.48
0.82
F-Score: 4
Z-Score: 19.03
M-Score: -0.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -233.00
CEMP's Operating margin (%) is ranked lower than
63% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. CEMP: -233.00 )
Ranked among companies with meaningful Operating margin (%) only.
CEMP' s 10-Year Operating margin (%) Range
Min: -549.34  Med: -469.86 Max: -390.38
Current: -233
-549.34
-390.38
Net-margin (%) -241.47
CEMP's Net-margin (%) is ranked lower than
64% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. CEMP: -241.47 )
Ranked among companies with meaningful Net-margin (%) only.
CEMP' s 10-Year Net-margin (%) Range
Min: -576.41  Med: -490.79 Max: -405.16
Current: -241.47
-576.41
-405.16
ROE (%) -72.67
CEMP's ROE (%) is ranked lower than
72% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CEMP: -72.67 )
Ranked among companies with meaningful ROE (%) only.
CEMP' s 10-Year ROE (%) Range
Min: -94.12  Med: -82.32 Max: -70.51
Current: -72.67
-94.12
-70.51
ROA (%) -50.81
CEMP's ROA (%) is ranked lower than
68% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. CEMP: -50.81 )
Ranked among companies with meaningful ROA (%) only.
CEMP' s 10-Year ROA (%) Range
Min: -191.64  Med: -60.35 Max: -53.06
Current: -50.81
-191.64
-53.06
ROC (Joel Greenblatt) (%) -6262.13
CEMP's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. CEMP: -6262.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CEMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -47405.52  Med: -36528.00 Max: -18139.82
Current: -6262.13
-47405.52
-18139.82
EBITDA Growth (3Y)(%) -64.50
CEMP's EBITDA Growth (3Y)(%) is ranked lower than
96% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. CEMP: -64.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CEMP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.6  Med: -65.90 Max: -64.5
Current: -64.5
-67.6
-64.5
EPS Growth (3Y)(%) -66.40
CEMP's EPS Growth (3Y)(%) is ranked lower than
97% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. CEMP: -66.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CEMP' s 10-Year EPS Growth (3Y)(%) Range
Min: -69.3  Med: -68.00 Max: -66.4
Current: -66.4
-69.3
-66.4
» CEMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CEMP Guru Trades in Q4 2013

First Eagle Investment 780,275 sh (-40.38%)
» More
Q1 2014

CEMP Guru Trades in Q1 2014

First Eagle Investment Sold Out
» More
Q1 2015

CEMP Guru Trades in Q1 2015

Paul Tudor Jones 15,611 sh (New)
» More
Q2 2015

CEMP Guru Trades in Q2 2015

Paul Tudor Jones 10,977 sh (-29.68%)
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.03
CEMP's P/B is ranked lower than
78% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. CEMP: 9.03 )
Ranked among companies with meaningful P/B only.
CEMP' s 10-Year P/B Range
Min: 2.35  Med: 8.03 Max: 20.32
Current: 9.03
2.35
20.32
P/S 44.77
CEMP's P/S is ranked lower than
79% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. CEMP: 44.77 )
Ranked among companies with meaningful P/S only.
CEMP' s 10-Year P/S Range
Min: 22.55  Med: 47.00 Max: 73.6
Current: 44.77
22.55
73.6
Current Ratio 9.54
CEMP's Current Ratio is ranked higher than
74% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. CEMP: 9.54 )
Ranked among companies with meaningful Current Ratio only.
CEMP' s 10-Year Current Ratio Range
Min: 2.48  Med: 9.86 Max: 30.34
Current: 9.54
2.48
30.34
Quick Ratio 9.54
CEMP's Quick Ratio is ranked higher than
74% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. CEMP: 9.54 )
Ranked among companies with meaningful Quick Ratio only.
CEMP' s 10-Year Quick Ratio Range
Min: 2.48  Med: 9.86 Max: 30.34
Current: 9.54
2.48
30.34
Days Sales Outstanding 46.09
CEMP's Days Sales Outstanding is ranked higher than
65% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. CEMP: 46.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
CEMP' s 10-Year Days Sales Outstanding Range
Min: 56.37  Med: 66.17 Max: 75.96
Current: 46.09
56.37
75.96

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.35
CEMP's Price/Net Cash is ranked lower than
58% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. CEMP: 9.35 )
Ranked among companies with meaningful Price/Net Cash only.
CEMP' s 10-Year Price/Net Cash Range
Min: 2.64  Med: 5.32 Max: 16.1
Current: 9.35
2.64
16.1
Price/Net Current Asset Value 9.02
CEMP's Price/Net Current Asset Value is ranked lower than
60% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. CEMP: 9.02 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CEMP' s 10-Year Price/Net Current Asset Value Range
Min: 2.62  Med: 5.20 Max: 14.51
Current: 9.02
2.62
14.51
Price/Tangible Book 9.02
CEMP's Price/Tangible Book is ranked lower than
71% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. CEMP: 9.02 )
Ranked among companies with meaningful Price/Tangible Book only.
CEMP' s 10-Year Price/Tangible Book Range
Min: 2.61  Med: 5.16 Max: 14.42
Current: 9.02
2.61
14.42
Price/Median PS Value 0.95
CEMP's Price/Median PS Value is ranked higher than
52% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. CEMP: 0.95 )
Ranked among companies with meaningful Price/Median PS Value only.
CEMP' s 10-Year Price/Median PS Value Range
Min: 0.53  Med: 0.98 Max: 1.17
Current: 0.95
0.53
1.17
Earnings Yield (Greenblatt) (%) -5.30
CEMP's Earnings Yield (Greenblatt) (%) is ranked higher than
55% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. CEMP: -5.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CEMP' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -6.6  Med: 0.00 Max: 0
Current: -5.3
-6.6
0

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 24 34 113 204
EPS($) -1.77 -1.83 -1.30 -0.30
EPS without NRI($) -1.77 -1.83 -1.30 -0.30

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:9C1.Germany,
Cempra Inc is the successor entity of Cempra Pharmaceuticals, Inc. which was incorporated on November 18, 2005 and commenced operations in January 2006. The Company is a clinical-stage pharmaceutical company which is engaged in the development of differentiated antibiotics for the acute care and community settings to meet critical medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Company's main product, solithromycin (CEM-101), is in Phase 3 clinical trials. The Company is developing solithromycin in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP. Solithromycin is a potent new fourth generation macrolide and the first fluoroketolide in clinical development. The Company is also completed a Phase 2 study of solithromycin in uncomplicated gonorrhea. Its second program is Taksta, which the Company is developing in the U.S. as a long term oral treatment for prosthetic joint infections caused by staphylococci, including S. aureus and MRSA. The Company is conducting a Phase 2 trial for Taksta in patients with prosthetic joint infections and have submitted a proposal for a Phase 3 trial for Tasksta as a treatment for PJI. The Company has licensed solithromycin to Toyama Chemical Co., Ltd. for development and commercialization in Japan while retaining the rights to the rest of the world. The Company is developing Taksta in the U.S. as a long term oral treatment of prosthetic joint infections, or PJI, caused by staphylococci, including S. aureus and methicillin-resistant Staphylococcus aureus, or MRSA.
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
Does Cempra Have The Next Blockbuster Drug? Jan 08 2015 

More From Other Websites
Cempra to Present at Three Upcoming Investor Conferences Sep 03 2015
CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 19 2015
FDA Grants Fast Track Designation to Cempra for Solithromycin in the Treatment of Community Acquired... Aug 19 2015
Coverage initiated on Cempra by Morgan Stanley Aug 13 2015
CEMPRA, INC. Financials Aug 05 2015
Cempra to Present at the Wedbush PacGrow 2015 Healthcare Conference Aug 04 2015
3 Biotech Stocks to Buy With Huge Catalysts Coming Soon Aug 03 2015
Edited Transcript of CEMP earnings conference call or presentation 29-Jul-15 8:30pm GMT Jul 29 2015
Cempra reports 2Q loss Jul 29 2015
Cempra reports 2Q loss Jul 29 2015
Cempra Inc Earnings Call scheduled for 4:30 pm ET today Jul 29 2015
CEMPRA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 29 2015
Cempra Reports Second Quarter 2015 Financial Results and Provides Corporate Update Jul 29 2015
Cempra to Report Second Quarter 2015 Financial Results Jul 22 2015
New loan agreement would give Chapel Hill drug firm a cash runway Jul 17 2015
CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a... Jul 16 2015
Chapel Hill drug developer Cempra sees stock bounce on pneumonia trial Jul 07 2015
CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 07 2015
Cempra Completes Patient Enrollment of Solitaire-IV Phase 3 Clinical Trial Jul 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK